GR3006561T3 - - Google Patents

Info

Publication number
GR3006561T3
GR3006561T3 GR920402935T GR920402935T GR3006561T3 GR 3006561 T3 GR3006561 T3 GR 3006561T3 GR 920402935 T GR920402935 T GR 920402935T GR 920402935 T GR920402935 T GR 920402935T GR 3006561 T3 GR3006561 T3 GR 3006561T3
Authority
GR
Greece
Prior art keywords
protein products
products
viruses
inactivate
precipitating
Prior art date
Application number
GR920402935T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3006561T3 publication Critical patent/GR3006561T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y10S424/807—Monoclonal
    • Y10S424/808—Human
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y10S530/865—Human

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GR920402935T 1988-12-20 1992-12-16 GR3006561T3 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/287,368 US4939176A (en) 1988-12-20 1988-12-20 Viral inactivation process

Publications (1)

Publication Number Publication Date
GR3006561T3 true GR3006561T3 (enExample) 1993-06-30

Family

ID=23102591

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920402935T GR3006561T3 (enExample) 1988-12-20 1992-12-16

Country Status (9)

Country Link
US (1) US4939176A (enExample)
EP (1) EP0374625B1 (enExample)
JP (1) JP2601551B2 (enExample)
AT (1) ATE82510T1 (enExample)
AU (1) AU618157B2 (enExample)
CA (1) CA1340211C (enExample)
DE (1) DE68903558T2 (enExample)
ES (1) ES2052872T3 (enExample)
GR (1) GR3006561T3 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001367A1 (en) * 1989-07-20 1991-02-07 Bioeng, Inc. Supercritical fluid disruption of and extraction from microbial cells
US5202246A (en) * 1989-08-16 1993-04-13 Armour Pharmaceutical Company Treatment of immobilized matrices for preparation of pharmaceutical and biological products with anti-microbial agents to remove pyrogen-producing organisms and pyrogens
AU6428390A (en) * 1989-08-16 1991-04-03 Rorer International (Overseas) Inc. Treatment of immobilized matrices with antimicrobial agents to remove pyrogen-producing organisms and pyrogens
JPH0671434B2 (ja) * 1989-09-18 1994-09-14 株式会社ミドリ十字 ヒト血清アルブミンの製造方法
ES2074490T5 (es) * 1990-03-22 2004-02-16 Biotest Pharma Gmbh Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa.
AT408191B (de) * 1991-08-19 2001-09-25 Haemosan Erzeugung Pharmazeuti Verfahren zur inaktivierung von prionen
US5486293A (en) * 1994-03-21 1996-01-23 Hemasure, Inc. Removal of small exogenous molecules from biological fluids
US5561115A (en) 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
AU717541B2 (en) * 1996-12-06 2000-03-30 Csl Limited Inactivation of viruses by incubation with caprylate
AUPO410696A0 (en) * 1996-12-06 1997-01-09 Csl Limited Inactivation of viruses by incubation with caprylate
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US20030133829A1 (en) * 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
AU2003211474A1 (en) * 2002-02-28 2003-09-09 Nipro Corporation Stabilized albumin preparaions
US20040022792A1 (en) * 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
EP2277915A1 (en) 2004-02-27 2011-01-26 Octapharma AG A purified, virus safe antibody preparation
CN1314447C (zh) * 2004-04-12 2007-05-09 爱华生物科技(香港)有限公司 一种具有抑制蛋白酶作用的药物的制备方法
EP1786827A4 (en) * 2004-05-14 2008-10-29 Kirin Holdings Kk PROCESS FOR IMMUNOGLOBULINE CLEANING
CA2666607C (en) * 2006-11-01 2015-02-10 Biogen Idec Ma Inc. Method of isolating biomacromolecules using low ph and divalent cations
AU2009236653B2 (en) * 2008-04-16 2014-09-25 Biogen Ma Inc. Method of isolating biomacromolecules using polyalkylene glycol and transition metals
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
DE102010054767B4 (de) 2010-12-16 2013-02-21 Previpharma Ag Verfahren zur Trennung, Aufkonzentration und/oder Reinigung von (Blut)Plasmaprotein, Viren oder Virenbestandteilen
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
AU2013205138B2 (en) 2012-08-09 2015-06-25 Grifols, S.A. Caprylate Viral Deactivation
SG11201603028SA (en) 2013-10-18 2016-05-30 Universität Für Bodenkultur Wien Purification of proteins
EP3068417B1 (en) * 2013-11-15 2023-12-27 F. Hoffmann-La Roche AG Methods for viral inactivation using eco-friendly detergents
CN106459142B (zh) * 2014-04-30 2021-07-13 诺和诺德股份有限公司 使用辛酸纯化蛋白质的方法
EP3628675A1 (en) 2015-06-26 2020-04-01 Ferring B.V. Methods of purification and/or viral inactivation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
JPS5874617A (ja) * 1981-10-28 1983-05-06 Green Cross Corp:The 人由来血液凝固第７因子含有水溶液の加熱処理方法
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4534972A (en) * 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
US4762714A (en) * 1986-04-08 1988-08-09 Miles Laboratories, Inc. Preparation of retrovirus-free immunoglobulins
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue

Also Published As

Publication number Publication date
EP0374625A3 (en) 1991-08-07
DE68903558D1 (de) 1992-12-24
ATE82510T1 (de) 1992-12-15
AU618157B2 (en) 1991-12-12
ES2052872T3 (es) 1994-07-16
EP0374625A2 (en) 1990-06-27
DE68903558T2 (de) 1993-04-01
JP2601551B2 (ja) 1997-04-16
US4939176A (en) 1990-07-03
JPH02273175A (ja) 1990-11-07
AU4698789A (en) 1990-06-28
CA1340211C (en) 1998-12-15
EP0374625B1 (en) 1992-11-19

Similar Documents

Publication Publication Date Title
GR3006561T3 (enExample)
EP0124506A3 (en) Method of inactivating pathogens
DE3674941D1 (de) Ozonentkeimung von blut und blutprodukten.
DK0400958T3 (da) Levende vacciner
DK160181C (da) Anvendelse af en varmesteriliserbar vandig oploesning til opbevaring af roede blodlegemer, et sammensat blodposesystem omfattende en pose med en saadan vandig oploesning samt en varmesteriliserbar blodpose af plast til brug i det sammmensatte blodposesystem indeholdende en saadan vandig oploesning
AU8168187A (en) Pasteurization of immunoglobulin solutions
ATE72127T1 (de) Sterilisationsverfahren.
ES2056108T3 (es) Empleo de interacciones anticuerpo/antigeno para proteger o modular la actividad biologica.
ATE257016T1 (de) Herstellung von virusinaktivierten intravenös injektierbaren globulin aus immunserum
ATE168717T1 (de) Zellkulturverfahren und medium für das wachstum adhärenter tierzellen
GR930300100T1 (enExample)
EP0125105A3 (en) Immobilization of catalytically active microorganisms in agar gel fibers
ES2077707T3 (es) Procedimiento para la inactivacion de la actividad biologica de adn.
FI892769A0 (fi) Foerfarande foer inaktivering av den rekombinanta dna:n.
Vais et al. Amperometric electrode for glucose with immobilized bacteria(Pseudomonas fluorescens).
DE3479744D1 (en) Associations of prokaryotic organisms and eukaryotic plant cells
EP0497820A4 (en) Ribozyme inhibitors
FR2638234B1 (fr) Support pour molecules biologiquement actives ou lui-meme biologiquement actif, son procede de preparation et son application en biologie
Akanji et al. Effect of repeated administration of suramin on alkaline phosphatase activity in rat kidney.
Dube et al. Effect of fungicides on pectolytic enzyme production by Verticillium albo-atrum.
JPS6463600A (en) Method for purifying vitronectin
Defrank Thermostable bacterial enzymes for decontamination.
Drummond et al. The interaction of nitrous oxide with cobalamin-dependent methionine synthase
Zamshor et al. Beef-extract agar with sodium nucleinate as a medium for storage and stabilization of biological properties of shigellas.
ATE66611T1 (de) Verwendung biologisch aktiver copolymere zur herstellung eines arzneimittels zur stimulierung des wachstums von tieren.